-
Professor Pei Dong: Continuously Exploring Individualized Treatment Strategies for Advanced Kidney Cancer in China
Kidney cancer is one of the three major tumors of the urinary system. According to statistics, in 2022, there were approximately 77,000 new cases and 46,000 deaths from kidney cancer in China. The prognosis for advanced metastatic kidney cancer is poor, with a five-year overall survival rate of less than 20% with targeted therapy alone.…
-
Prophylactic Infusion of Donor-Derived CD7 CAR-T Cells Post-Allo-HSCT for Treating R/R T-ALL/LBL
Recent clinical studies have shown that CD7-targeted chimeric antigen receptor T-cell (CAR-T) therapy is effective and safe for patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL/LBL). Combining CAR-T therapy with transplantation has the potential to enhance treatment efficacy and reduce disease recurrence. Most existing studies have implemented CD7 CAR-T cells as a bridge to allogeneic hematopoietic…
-
EHA Expert Interview | Three Studies from Professor Sanbin Wang’s Team Selected for EHA: An In-Depth Review
The 29th European Hematology Association (EHA) Annual Congress was held in Madrid, Spain, from June 13 to 16, 2024. As the largest international conference in the field of hematology in Europe, it attracts experts and scholars worldwide to share and discuss innovative ideas and the latest scientific and clinical research achievements in hematology. At this…
-
BOC/BOA 2024丨Professor Xiaojie Bian: Radioligand Therapy & PROTAC Treatment Bring New Hope for mCRPC
From July 5 to 7, 2024, the 2024 Annual Progress Seminar of Chinese Clinical Oncology (BOC) and Beast of ASCO® 2024 China (BOC/BOA) was grandly held in Guangzhou. On the 6th, Professor Xiaojie Bian from Fudan University Shanghai Cancer Center shared the latest drug development progress for metastatic castration-resistant prostate cancer (mCRPC) from the 2024…
-
Embrace the synergy of global expertise and local insights with Professor Zefei Jiang at the 2024 Best of ASCO/Best of CSCO.
As the Vice Chairman and Secretary-General of the Chinese Society of Clinical Oncology (CSCO), he leads the charge in aligning Chinese clinical oncology with international standards. Experience the cutting-edge advancements in targeted therapies, immunotherapies, and the integration of precision medicine. Let’s innovate together for a future where cancer treatment knows no borders.
-
Pre-ACLF and Other Different Clinical Courses of Acute Decompensated Cirrhosis
ACLF Monthly Review” is a special academic review column on ACLF invited by the editorial department of Hepatology Digest, created by the Chinese Acute-on-Chronic Liver Failure Consortium (Ch-CLIF-C). Each month, this column focuses on a specific area related to ACLF, aiming to popularize the concept and significance of ACLF and help readers quickly understand developments…
-
BOC/BOA Innovation Forum | Professor Jun Guo and ProfessorPei Dong: An Overview of Advances in Kidney Cancer Treatment and the Pulse of Combination Therapy
From July 5-7, 2024, the 2024 Chinese Clinical Oncology Annual Progress Seminar (BOC) and Beast of ASCO® 2024 China were grandly held in Guangzhou. On the 6th, a special session on urinary system tumors convened, gathering significant progress from ASCO. In the field of kidney cancer treatment, besides international advancements, China has made significant strides…
-
Professor Songqing Ye: Heterogeneity in HER2 Expression in Breast Cancer and Novel ADC Treatment Strategies
In recent years, the accurate detection of HER2 (human epidermal growth factor receptor 2) expression in breast cancer has become crucial for guiding personalized treatment strategies. However, the heterogeneity of HER2 expression, including spatial and temporal heterogeneity, poses challenges for clinical decision-making. In this article, Professor Songqing Ye from Fujian Provincial Hospital delves into the…
Connecting Medical Expertise through Media